Ovalbumin peptide-Major Histocompatibility Complex complex (OVA-pMHC)

Ovalbumin (OVA) presented via the Major Histocompatibility Complex (MHC) is a fundamental model system in immunology used to study antigen processing, presentation, and T-cell activation (UniProt: P01012). In this model, the chicken-derived protein ovalbumin is either expressed endogenously by cells or taken up by professional antigen-presenting cells, where it is proteolytically cleaved into specific immunodominant peptides. The most widely studied peptide is the MHC Class I-restricted SIINFEKL (OVA 257-264), which is presented by the murine H-2Kb molecule and recognized by OT-I T-cell receptors (Nature 1990; 348:337-339). This target complex is essential for evaluating the potency of adoptive T-cell therapies, vaccines, and various immunomodulatory agents in preclinical mouse models (Cell 1994; 76:17-27). While ovalbumin is not a human disease-associated antigen, it serves as a surrogate for tumor-associated antigens or viral proteins to validate therapeutic concepts. In research settings, drugs such as TCR-engineered T cells or bispecific T-cell engagers are designed to recognize this pMHC complex to induce targeted cell lysis. The system allows for precise quantification of immune responses, making it a gold standard for understanding the dynamics of the immune synapse and peripheral tolerance.

Other names

OVA-MHC complexSIINFEKL-H-2Kb complexOvalbumin-derived antigenpMHC complex (OVA)

Recognition of the peptide-MHC complex by specific T-cell receptors (TCRs) or TCR-like antibodies, leading to T-cell activation, cytokine secretion, and targeted destruction of the presenting cell.